Literature DB >> 20037762

Sildenafil improves scotoma after posterior cerebral infarctions: a case report.

Peter Schlindwein, B M Eicke, P Stoeter, M Dieterich.   

Abstract

A 65-year-old man had an embolic stroke of both posterior cerebral arteries in 2002. Two years later he noted rapid improvement of the residual bilateral inferior quadrant anopia whenever he took 25 mg sildenafil. The improvement of scotomas was verified by visual field examinations and persisted reproducibly for 3-7 days. An overlay of a subtraction of functional magnetic resonance imaging (MRI) during visual stimulation before and after medication onto a T1-weighted MRI of the patient revealed additional activations along the margins of the old cerebral infarctions. These findings and the additional results of a perfusion MRI suggest that phosphodiesterase 5 inhibitors may prove beneficial in the rehabilitative course after ischemic strokes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20037762     DOI: 10.1007/s00415-009-5434-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  9 in total

1.  The effect of global cerebral vasodilation on focal activation hemodynamics.

Authors:  Bojana Stefanovic; Jan M Warnking; Karin M Rylander; G Bruce Pike
Journal:  Neuroimage       Date:  2005-12-05       Impact factor: 6.556

2.  Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats.

Authors:  Ruilan Zhang; Ying Wang; Li Zhang; Zhenggang Zhang; Wayne Tsang; Mei Lu; Lijie Zhang; Michael Chopp
Journal:  Stroke       Date:  2002-11       Impact factor: 7.914

3.  Direction-dependent visual cortex activation during horizontal optokinetic stimulation (fMRI study).

Authors:  Sandra Bense; Barbara Janusch; Peter Schlindwein; Thomas Bauermann; Goran Vucurevic; Thomas Brandt; Peter Stoeter; Marianne Dieterich
Journal:  Hum Brain Mapp       Date:  2006-04       Impact factor: 5.038

Review 4.  Past, present, and future: a 7-year update of Viagra (sildenafil citrate).

Authors:  G Jackson; H Gillies; I Osterloh
Journal:  Int J Clin Pract       Date:  2005-06       Impact factor: 2.503

Review 5.  Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction.

Authors:  Alan Laties; Ira Sharlip
Journal:  J Sex Med       Date:  2006-01       Impact factor: 3.802

6.  Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension.

Authors:  B Rosengarten; R T Schermuly; R Voswinckel; M G Kohstall; H Olschewski; N Weissmann; W Seeger; M Kaps; F Grimminger; H A Ghofrani
Journal:  Cerebrovasc Dis       Date:  2005-12-23       Impact factor: 2.762

7.  The effects of sildenafil on ocular blood flow.

Authors:  Murat Koksal; Huseyin Ozdemir; Sebnem Kargi; Cetin Yesilli; Sühan Tomaç; Kamran Mahmutyazicioglu; Aydin Mungan
Journal:  Acta Ophthalmol Scand       Date:  2005-06

8.  Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor.

Authors:  Li Zhang; Rui Lan Zhang; Ying Wang; Chunling Zhang; Zheng Gang Zhang; He Meng; Michael Chopp
Journal:  Stroke       Date:  2005-03-03       Impact factor: 7.914

9.  Visual short-term effects of Viagra: double-blind study in healthy young subjects.

Authors:  Herbert Jägle; Christine Jägle; Ludwig Sérey; Alice Yu; Albrecht Rilk; Bettina Sadowski; Dorothea Besch; Eberhart Zrenner; Lindsay T Sharpe
Journal:  Am J Ophthalmol       Date:  2004-05       Impact factor: 5.258

  9 in total
  2 in total

Review 1.  The Role of Sildenafil in Treating Brain Injuries in Adults and Neonates.

Authors:  Ying Xiong; Pia Wintermark
Journal:  Front Cell Neurosci       Date:  2022-05-10       Impact factor: 6.147

2.  The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.

Authors:  Mathilde Mh Pauls; Barry Moynihan; Thomas R Barrick; Christina Kruuse; Jeremy B Madigan; Atticus H Hainsworth; Jeremy D Isaacs
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-19       Impact factor: 6.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.